During the past decade, Pennsylvania Regional Center for Arthritis and Osteoporosis Research conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 6 clinical trials were completed, i.e. on average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 2 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Pennsylvania Regional Center for Arthritis and Osteoporosis Research" #1 sponsor was "Eli Lilly and Company" with 5 trials, followed by "Hoffmann-La Roche" with 2 trials sponsored, "Galapagos NV" with 1 trials sponsored, "Gilead Sciences" with 1 trials sponsored and "Sequenom, Inc." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Pennsylvania Regional Center for Arthritis and Osteoporosis Research" #1 collaborator was "Incyte Corporation" with 2 trials as a collaborator, "Galapagos NV" with 1 trials as a collaborator, "Gilead Sciences" with 1 trials as a collaborator and "Laboratory Corporation of America" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Pennsylvania Regional Center for Arthritis and Osteoporosis Research" are "Rheumatoid Arthritis" (5 trials), "Psoriatic Arthritis" (3 trials), "Plaque Psoriasis" (1 trials) and "Rheumatoid Arthritis (RA)" (1 trials). Many other conditions were trialed in "Pennsylvania Regional Center for Arthritis and Osteoporosis Research" in a lesser frequency.

Most popular intervention types in "Pennsylvania Regional Center for Arthritis and Osteoporosis Research" are "Drug" (9 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Baricitinib" (2 trials), "Filgotinib" (2 trials), "Ixekizumab" (2 trials) and "Placebo to match filgotinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Pennsylvania Regional Center for Arthritis and Osteoporosis Research" are 10 trials for "All" genders.

Currently, there are NaN active trials in "Pennsylvania Regional Center for Arthritis and Osteoporosis Research". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Pennsylvania Regional Center for Arthritis and Osteoporosis Research, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Pennsylvania Regional Center for Arthritis and Osteoporosis Research, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 0 trials that are defined as “Not Applicable".